Progenity Provides Results from Key Study for Its Targeted Therapeutics Program
SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced results from a further study for the company’s Targeted Therapeutics program. The study evaluated delivery…